Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 3/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29435968 | 1.00 | TSHR (0.39) | TSHRCYP3A4TP53ALDH1A1MAPK1 | |
| SCHEMBL17649942 | 0.81 | TSHR (0.40) | TSHRCYP3A4TP53ALDH1A1MAPK1 | |
| SCHEMBL3818037 | 0.79 | TSHR (0.39) | TSHRCYP3A4TP53ALDH1A1MAPK1 | |
| SCHEMBL159290 | 0.79 | ALDH1A1 (0.40) | TSHRCYP3A4TP53ALDH1A1MAPK1 | |
| SCHEMBL29658929 | 0.79 | ALDH1A1 (0.40) | TSHRCYP3A4TP53ALDH1A1MAPK1 | |
| SCHEMBL4458219 | 0.77 | CYP3A4 (0.41) | TSHRCYP3A4TP53MAPK1TDP1 | |
| SCHEMBL18935880 | 0.77 | NOTUM (0.40) | TSHRCYP3A4ALDH1A1MAPK1CA12 | |
| SCHEMBL4847774 | 0.75 | ALOX15 (0.43) | TSHRCYP3A4ALDH1A1MAPK1CA12 | |
| SCHEMBL7460667 | 0.75 | CA1 (0.43) | TSHRCYP3A4TP53ALDH1A1MAPK1 | |
| SCHEMBL159571 | 0.75 | PTGER4 (0.33) | TSHRCYP3A4ALDH1A1MAPK1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114230471-B | Preparation method of 3, 4-dichloro-2-fluoroaniline | 河北科技大学 | 2024-01-26 | — | — | CN | claimed |
| CN-114230471-A | Preparation method of 3, 4-dichloro-2-fluoroaniline | 河北科技大学 | 2022-03-25 | — | — | CN | claimed |
| EP-2611797-B1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | HANMI SCIENCE CO LTD (KR) | 2016-12-28 | — | — | EP | claimed |
| CN-103237801-B | Quinoline or quinazoline derivatives having apoptosis-inducing activity on cells | HANMI HOLDINGS Co.,Ltd. (KR) | 2015-11-25 | — | — | CN | claimed |
| US-8835458-B2 | Quinoline or quinazoline derivatives with apoptosis inducing activity on cells | HANMI SCIENCE CO., LTD (KR) | 2014-09-16 | — | — | US | claimed |
| EP-2611797-A2 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | Hanmi Science Co., Ltd. (KR) | 2013-07-10 | — | — | EP | claimed |
| US-20130165386-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | HANMI SCIENCE CO., LTD (KR) | 2013-06-27 | — | — | US | claimed |
| WO-2012030160-A2 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | HANMI HOLDINGS CO., LTD. (KR) | 2012-03-08 | — | — | WO | claimed |
| EP-3398939-B1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY | ANCUREALL PHARMACEUTICAL SHANGHAI CO LTD (CN) | 2026-05-06 | — | — | EP | disclosed |
| EP-4013749-B1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12564638-B2 | EGFR protein degradant and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2026-03-03 | — | — | US | disclosed |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12435046-B2 | Alkynyl quinazoline compounds | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ARTHROSI THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20100009974-A1 | Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compostions containing them | LES LABORATOIRES SERVIER (FR) | 2010-01-14 | — | — | US | disclosed |
| WO-2010004139-A1 | NEW CYCLOALKYLATED BENZOTHIADIAZINE DERIVATIVES, METHOD FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2010-01-14 | — | — | WO | disclosed |
| WO-2009080533-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
| WO-2008150118-A2 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | HANMI PHARM. CO., LTD. (KR) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008002039-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING THE GROWTH OF CANCER CELL | HANMI PHARM. CO., LTD. (KR) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435046-B2 | Alkynyl quinazoline compounds | GLS, GLS2, MCL1 | TSHR 2974/4885CYP3A4 3363/4885TP53 28/4885 |
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | EGFR, ABL1, ERBB2 | TSHR 3230/4885CYP3A4 2610/4885TP53 6/4885 |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, MTNR1A | TSHR 308/4885CYP3A4 739/4885TP53 4882/4885 |
| US-20130165386-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | CASP7, API5, BAX | TSHR 4776/4885CYP3A4 2789/4885TP53 29/4885 |
| US-20100009974-A1 | Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compostions containing them | ACLY, HCAR1, GABRG1 | TSHR 442/4885CYP3A4 299/4885TP53 3859/4885 |
| US-12564638-B2 | EGFR protein degradant and anti-tumor application thereof | EGFR, ERBB2, ERBB3 | TSHR 807/4885CYP3A4 4009/4885TP53 7/4885 |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, BCL6 | TSHR 730/4885CYP3A4 1572/4885TP53 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.